Journal of Neuromuscular Diseases - Volume 2, issue 1

Authors: Alexander, Matthew S. | Kunkel, Louis M.

Article Type: Review Article

Abstract: MicroRNAs (miRNAs) are small 21–24 nucleotide RNAs that are capable of regulating multiple signaling pathways across multiple tissues. MicroRNAs are dynamically regulated and change in expression levels during periods of early development, tissue regeneration, cancer, and various other disease states. Recently, microRNAs have been isolated from whole serum and muscle biopsies to identify unique diagnostic signatures for specific neuromuscular disease states. Functional studies of microRNAs in cell lines and animal models of neuromuscular diseases have elucidated their importance in contributing to neuromuscular disease progression and pathologies. The ability of microRNAs to alter the expression of an entire signaling pathway opens …up their unique ability to be used as potential therapeutic entry points for the treatment of disease. Here, we will review the recent findings of key microRNAs and their dysregulation in various neuromuscular diseases. Additionally, we will highlight the current strategies being used to regulate the expression of key microRNAs as they have become important players in the clinical treatment of some of the neuromuscular diseases. Show more

Keywords: MicroRNA, skeletal muscle, muscle disease, dystrophy, biomarker, therapy

DOI: 10.3233/JND-140058

Citation: Journal of Neuromuscular Diseases, vol. 2, no. 1, pp. 1-11, 2015

Authors: Allenbach, Y. | Benveniste, O.

Article Type: Review Article

Abstract: To date, there are four main groups of idiopathic inflammatory myopathies (IIM): polymyositis (PM), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) and sporadic inclusion body myositis; based on clinical presentation and muscle pathology. Nevertheless, important phenotypical differences (either muscular and/or extra-muscular manifestations) within a group persist. In recent years, the titration of different myositis-specific (or associated) auto-antibodies as a diagnostic tool has increased. This is an important step forward since it may facilitate, at a viable cost, the differential diagnosis between IIM and other myopathies. We have now routine access to assays for the detection of different antibodies. For example, IMNM …are related to the presence of anti-SRP or anti-HMGCR. PM is associated with anti-synthetase antibodies (anti-Jo-1, PL-7, PL-12, OJ, and EJ) and DM with anti-Mi-2, anti-SAE, anti-TIF-1-γ and anti-NXP2 (both associated with cancer) or anti-MDA5 antibodies (associated with interstitial lung disease). Today, over 30 myositis specific and associated antibodies have been characterised, and all groups of myositis may present one of those auto-antibodies. Most of them allow identification of homogenous patient groups, more precisely than the classical international classifications of myositis. This implies that classification criteria could be modified accordingly, since these auto-antibodies delineate groups of patients suffering from myositis with consistent clinical phenotype (muscular and extra-muscular manifestations), common prognostic (cancer association, presence of interstitial lung disease, mortality and risk of relapse) and treatment responses. Nevertheless, since numerous auto-antibodies have been recently characterised, the exact prevalence of myositis specific antibodies remains to be documented, and research of new auto-antibodies in the remaining seronegative group is still needed. Show more

Keywords: Myositis, polymyositis, dermatomyositis, idiopathic inflammatory myopathy, auto-antibody

DOI: 10.3233/JND-140054

Citation: Journal of Neuromuscular Diseases, vol. 2, no. 1, pp. 13-25, 2015

Authors: Bouchet-Séraphin, Céline | Vuillaumier-Barrot, Sandrine | Seta, Nathalie

Article Type: Review Article

Abstract: Dystroglycanopathies are neuromuscular disorders due to abnormal glycosylation of dystroglycan which is a cell-surface glycoprotein that acts as a receptor for extracellular matrix proteins containing laminin-G domains. The reduced ability of abnormally glycosylated α−DG to bind laminin is associated with abnormal neuronal migration and muscular dystrophy. Clinical manifestations are extremely variable, and include a wide spectrum of phenotypic severity: some mutations are associated with adult-onset Limb-girdle muscular dystrophy and other mutations with a congenital onset, determining the more complex disorder Congenital Muscular Dystrophy which includes severe structural brain and eye anomalies such as Muscle-Eye-Brain Disease, Walker-Warburg Syndrome, and Fukuyama Congenital …Muscular Dystrophy. So far, mutations in eighteen different genes have been identified in patients with dystroglycanopathies, all of them demonstrating autosomal recessive inheritance. Most genes code for glycosyltransferases (POMT1, POMT2, POMGNT1, LARGE, GTDC2, B4GAT1, B3GALNT2) although a minority does not (DPM1, DPM2, DPM3, DOLK, POMK, GMPPB). Others genes code for proteins of unknown function in the α−dystroglycan glycosylation (FKTN, FKRP, ISPD, and TMEM5) or α−dystroglycan itself, DAG1. The biochemical picture becomes a little bit more complete, but also more complex, with each new identified gene. In the majority of cases the identity of the defective gene cannot be predicted from the clinical phenotype. Considering the number of causative genes in dystroglycanopathies, targeted sequencing comprising genes of all glycosylation, whatever the type, would appear at present to be the best way of tackling molecular diagnosis. Show more

Keywords: (4-10) MeSH database, glycosylation, O-mannosylation, CMD, LGMD, WWS

DOI: 10.3233/JND-140047

Citation: Journal of Neuromuscular Diseases, vol. 2, no. 1, pp. 27-38, 2015

Authors: Gardner, Brandon B. | Swaggart, Kayleigh A. | Kim, Gene | Watson, Sydeaka | McNally, Elizabeth M.

Article Type: Research Article

Abstract: Background: The muscular dystrophies target muscle groups differentially. In mouse models of muscular dystrophy, notably the mdx model of Duchenne Muscular Dystrophy, the diaphragm muscle shows marked fibrosis and at an earlier age than other muscle groups, more reflective of the histopathology seen in human muscular dystrophy. Methods: Using a mouse model of limb girdle muscular dystrophy, the Sgcg mouse, we compared muscle pathology across different muscle groups and heart. A cohort of nearly 200 Sgcg mice were studied using multiple measures of pathology including echocardiography, Evans Blue dye uptake and hydroxyproline content in multiple muscle groups. Spearman rank correlations …were determined among echocardiographic and pathological parameters. Findings: The abdominal muscles were found to have more fibrosis than other muscle groups, including the diaphragm muscle. The abdominal muscles also had more Evans blue dye uptake than other muscle groups. The amount of diaphragm fibrosis was found to correlate positively with fibrosis in the left ventricle, and abdominal muscle fibrosis correlated with impaired left ventricular function. Fibrosis in the abdominal muscles negatively correlated with fibrosis in the diaphragm and right ventricles. Together these data reflect the recruitment of abdominal muscles as respiratory muscles in muscular dystrophy, a finding consistent with data from human patients. Show more

Keywords: Muscular dystrophy, heart, abdominal muscle, diaphragm muscle, fibrosis, membrane damage

DOI: 10.3233/JND-140062

Citation: Journal of Neuromuscular Diseases, vol. 2, no. 1, pp. 39-49, 2015

Authors: Accorsi, Anthony | Mehuron, Thomas | Kumar, Ajay | Rhee, Younghwa | Girgenrath, Mahasweta

Article Type: Research Article

Abstract: Background: Merosin-deficient congenital muscular dystrophy (MDC1A) is caused by a loss of Laminin-α2. Secondary manifestations include failed regeneration, inflammation, and fibrosis; however, specific pathomechanisms remain unknown. Objectives: Using the LAMA2DyW (DyW) mouse model of MDC1A, we sought to determine if Integrin-αV and -α5, known drivers of pathology in other diseases, are dysregulated in dystrophic muscle. Additionally, we investigated whether Losartan, a drug previously shown to be antifibrotic in dystrophic scenarios, rescues integrin overexpression in DyW mice. Methods: qRT-PCR, ELISA, and immunohistochemistry were utilized to characterize integrin and matricellular protein dysregulation in hind limb muscles from WT and untreated/ Losartan-treated …DyW mice. Results: Integrin-αV and –α5 are significantly upregulated on both gene and protein level in DyW muscle- Losartan treatment attenuates this dysregulation. Immunohistochemistry showed that Integrin-αV is expressed on both infiltrating cells as well as on muscle cells- Losartan attenuates expression in both compartments. In addition, transcriptional overexpression of common matricellular and beta binding partners is rescued close to WT levels with Losartan. Lastly, latent and active TGF-β are upregulated in the serum of DyW mice, but only active TGF-β levels are attenuated by Losartan treatment. Conclusions: Our results suggest that overexpression of Integrin-αV and –α5 are likely contributing to secondary pathologies in MDC1A. We also believe that downregulation of Integrin-αV could be partially responsible for Losartan's antifibrotic effect and therefore could serve as a novel therapeutic target in MDC1A and other degenerative fibrotic diseases. Show more

Keywords: MDC1A, Congenital muscular dystrophy, ECM, Integrin, TGF-β

DOI: 10.3233/JND-140042

Citation: Journal of Neuromuscular Diseases, vol. 2, no. 1, pp. 51-61, 2015

Authors: Landfeldt, Erik | Lindgren, Peter | Bell, Christopher F. | Schmitt, Claude | Guglieri, Michela | Straub, Volker | Lochmüller, Hanns | Bushby, Katharine

Article Type: Research Article

Abstract: Background: International care guidelines for Duchenne muscular dystrophy (DMD) were published in 2010, but compliance in clinical practice is unknown. Objective: The objective of our study was to compare real-world DMD care in Germany, Italy, the UK, and the US with the clinical recommendations. Methods: DMD patients from Germany, Italy, the UK, and the US were identified through Translational Research in Europe – Assessment & Treatment of Neuromuscular Diseases (TREAT-NMD) registries and invited with a caregiver to complete a questionnaire with questions regarding DMD-related healthcare. Estimates of care were stratified by disease stage (early/late ambulatory/non-ambulatory) and compared against the care …guidelines. Results: A total of 770 patients (173 German, 122 Italian, 191 UK, and 284 US) completed the questionnaire. Poor compliance to guidelines of routine follow-up by neuromuscular, cardiac, and respiratory specialists, physiotherapy, and access to medical devices and aids were observed in all countries. Less than 27% (209 of 770) of patients met all absolute recommendations, ranging from 9% (11 of 122) in Italy to 37% (70 of 191) in the UK, and from 49% (76 of 155) in the early ambulatory class to 16% (33 of 205) in the late non-ambulatory class. Conclusions: We show that the medical management of DMD varies substantially between Germany, Italy, the UK, and the US. Experience of real-world DMD care appears to be in poor agreement with the DMD clinical guidelines and increased compliance is urgently needed to improve treatment outcomes and enable patients to lead fulfilling, independent lives into adulthood. Show more

Keywords: Muscular dystrophy, duchenne, practice guideline, delivery of health care, observational study

DOI: 10.3233/JND-140053

Citation: Journal of Neuromuscular Diseases, vol. 2, no. 1, pp. 63-72, 2015

Authors: Deenen, Johanna C.W. | Horlings, Corinne G.C. | Verschuuren, Jan J.G.M. | Verbeek, André L.M. | van Engelen, Baziel G.M.

Article Type: Research Article

Abstract: Background: In 1991, the first world survey of neuromuscular disorders (NMDs) was published in the peer reviewed literature. Since then, diagnostics have been greatly improved through genetic confirmation and consensus on criteria. This prompted us to search the scientific literature since 1990 for the epidemiology of NMDs. Objectives: To study occurrence rates, gender and age distribution. Methods: Pubmed was searched for ‘epidemiology’, ‘incidence’ and ‘prevalence’ regarding thirty NMDs for peer reviewed literature from 1990–2014. Results: We found incidence rates for ten disorders, ranging from 0.05 to 9 per 100,000/yr. Most NMDs showed prevalence rates between 1 and 10 per 100,000 …population, except for multifocal motor neuropathy, Lambert-Eaton myasthenic syndrome, Emery-Dreifuss dystrophy, oculopharyngeal muscular dystrophy, and congenital muscular dystrophies, which were <1/100,000. Post-polio syndrome and Charcot-Marie-Tooth disease revealed prevalences >10/100,000. Information regarding incidence, prevalence, age distribution and gender was complete for eight disorders. No data were found for chronic inflammatory demyelinating polyneuropathy, neuralgic amyotrophy, progressive spinal muscular atrophy, McArdle's and Pompe's disease. For the 17 remaining disorders, information was partially available. Conclusions: Compared to 1991, prevalence rates of Becker muscular dystrophy, facioscapulohumeral dystrophy, myotonic dystrophy and Charcot-Marie-Tooth disease showed increase, yet with highly overlapping ranges with the exception of myotonic dystrophy. The sum of the available prevalence rates comprises only the tip of the iceberg, but is already in range with the prevalence of Parkinson's disease. Although individual NMDs are rare, as a group they are not. Show more

Keywords: Neuromuscular diseases, epidemiology, incidence, prevalence

DOI: 10.3233/JND-140045

Citation: Journal of Neuromuscular Diseases, vol. 2, no. 1, pp. 73-85, 2015

Authors: Ceyhan-Birsoy, Ozge | Talim, Beril | Swanson, Lindsay C. | Karakaya, Mert | Graff, Michelle A. | Beggs, Alan H. | Topaloglu, Haluk

Article Type: Research Article

Abstract: Background: Congenital muscular dystrophies (CMDs) are a genetically and clinically heterogeneous group of neuromuscular disorders. Several genes encoding extracellular matrix, nuclear envelope, sarcolemmal proteins and glycosylation enzymes have been implicated in CMDs. The large overlap of clinical presentations due to mutations in different genes poses a challenge for clinicians in determining disease etiology for each patient. Objective: We investigated the use of whole exome sequencing (WES) in identifying the genetic cause of disease in 5 CMD patients from 3 families who presented with highly similar clinical features, including early-onset rapidly progressive weakness without brain or eye abnormalities. Methods: Whole exome …sequencing was performed on DNA from affected individuals. Potential functional impacts of mutations were investigated by immunostaining on available muscle biopsies. Results: Pathogenic mutations in 3 different genes, DYSF, FKTN, and ISPD were identified in each family. Mutation in DYSF led to absence of dysferlin protein in patient muscle. Mutations in ISPD led to impaired ISDP function, as demonstrated by deficiency of α-dystroglycan glycosylation in patient muscle. Conclusions: This study highlights the benefit of unbiased genomic approaches in molecular diagnosis of neuromuscular disorders with high clinical heterogeneity, such as the phenotypes observed in our patients. Our results suggest that dysferlin deficiency should be in the differential diagnosis of congenital and rapidly progressive muscular dystrophy, and therefore dysferlin antibody should be in the standard immunohistochemistry panel for muscle biopsies in cases with suspected CMD. Show more

Keywords: Muscular dystrophies, DYSF protein human, Dysferlinopathy, FKTN protein human, ISPD protein human, neuromuscular diseases, genetic testing

DOI: 10.3233/JND-140038

Citation: Journal of Neuromuscular Diseases, vol. 2, no. 1, pp. 87-92, 2015

Authors: Kassardjian, C.D. | Kokokyi, S. | Barnett, C. | Jewell, D. | Bril, V. | Murray, B.J. | Katzberg, H.D.

Article Type: Research Article

Abstract: Excessive daytime sleepiness (EDS) has not been investigated using objective tests in myasthenia gravis (MG). We investigated whether objective measurements of somnolence better detected abnormalities compared with sleepiness questionnaires in MG, and determine if MG patients have EDS. Eight patients with mild-to-moderate MG were recruited. Patients completed maintenance of wakefulness, overnight polysomnography, multiple sleep latency tests, Epworth Sleepiness Scale, and fatigue questionnaires. Seven patients demonstrated EDS on objective testing, while Epworth scores were abnormal in two, and the measures showed poor correlation. Our findings highlight that the ESS may be inadequate to diagnose EDS and lead to under-reporting of daytime …somnolence in patients with MG. Show more

Keywords: Myasthenia gravis, sleep, excessive daytime sleepiness, sleep apnea

DOI: 10.3233/JND-140057

Citation: Journal of Neuromuscular Diseases, vol. 2, no. 1, pp. 93-97, 2015

Authors: Denicourt, Maxime | Pham, Minh Trang | Mathieu, Jean | Breton, Robert

Article Type: Research Article

Abstract: Background and Objectives: A high risk of cardiac arrhythmias was reported in myotonic dystrophy type 1 (DM1). The purpose of the study was to evaluate the risk of severe electrocardiographic abnormalities in DM1 patients with small CTG expansions. Methods: We assessed the ECG done at DM1 diagnosis for 127 patients with ≤200 CTG repeats and for 82 of them who had ≥1 ECG over a period of follow-up of 11.7 ± 7.6 years (mean ± SD). Criteria of severe ECG abnormality are at least one of the following features: PR interval ≥240 msec, QRS duration ≥120 msec, second-degree or third-degree …atrioventricular block, atrial fibrillation or flutter, insertion of a pacemaker or cardioverter-defibrillator. Results: At baseline, ECG was normal for 109 patients out of 127 (85.8%) and only 4 patients (3.1%) presented severe ECG abnormalities. At follow-up, 46 patients out of 82 (56.1%) had a normal ECG and 25 (30.5%) developed severe ECG abnormalities (p < 0.0001) including 6 of them who needed permanent pacemaker insertion. There were also 3 sudden deaths during the follow-up period. Using multivariate Cox regression analysis, age at entry (relative risk RR, 1.05; (95% CI 1.01–1.08; p = 0.012) and muscular weakness (MIRS) at the entry (RR, 2.03; 95% CI 1.28–3.22; p = 0.003) were significant risk factors for the development of severe ECG abnormality. Conclusions: An increased risk of severe ECG abnormalitiesy and cardiac events is observed even in DM1 patients with small CTG expansions and warrants close cardiac follow-up similar to DM1 patients with larger CTG expansions. Show more

Keywords: Myotonic dystrophy, cardiac arrhythmias, electrocardiogram

DOI: 10.3233/JND-140025

Citation: Journal of Neuromuscular Diseases, vol. 2, no. 1, pp. 99-105, 2015